The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 24, 2017

Filed:

Sep. 04, 2015
Applicant:

Symphony Evolution, Inc., Rockville, MD (US);

Inventors:

Kenneth D. Rice, Mill Valley, CA (US);

Neel K. Anand, Burlingame, CA (US);

Joerg Bussenius, Foster City, CA (US);

Simona Costanzo, Los Altos, CA (US);

Abigail R. Kennedy, San Leandro, CA (US);

Csaba J. Peto, Alameda, CA (US);

Tsze H. Tsang, El Cerrito, CA (US);

Charles M. Blazey, San Francisco, CA (US);

Assignee:

SYMPHONY EVOLUTION, INC., Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 239/94 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 451/06 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 493/04 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); A61K 31/5513 (2006.01); A61K 31/553 (2006.01); A61K 31/7064 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/553 (2013.01); A61K 31/5513 (2013.01); A61K 31/7064 (2013.01); C07D 239/94 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 451/06 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 493/04 (2013.01);
Abstract

The present invention provides compounds of structural formula I, for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include 'spectrum selective' kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.


Find Patent Forward Citations

Loading…